Skip to main content

Science 37 Wins 2024 MedTech Breakthrough Award for “Clinical Efficiency Innovation”

Written by Customer Service on . Posted in Public Companies.

Science 37’s Patient Recruitment Recognized in Prestigious International Annual Awards Program for Standout Digital Health & Medical Technology Products and Companies

RESEARCH TRIANGLE PARK, N.C., May 09, 2024 (GLOBE NEWSWIRE) — Science 37 Holdings, Inc., today announced its selection as winner of the “Clinical Efficiency Innovation Award” in the 8th annual MedTech Breakthrough Awards program.

MedTech Breakthrough, an independent market intelligence organization, recognized Science 37 for its transformative solution to clinical research patient recruitment. By leveraging its nationwide medical licensure and AI-powered patient screening capabilities, Science 37’s Patient Recruitment solution engages, medically qualifies, and delivers fully consented participants to sites prior to their first study visit. This unique approach creates a better patient experience, increases patient randomization rates, improves site satisfaction, and nearly eliminates patients being redirected to competing studies.

“We understand the difficulty in turning referrals into consented participants and have worked hard to address these issues by revolutionizing the conventional approaches head-on,” said Erica Prowisor, SVP Patient and Site Networks at Science 37. “This award from MedTech Breakthrough highlights our work to mitigate the core challenges of conventional recruitment methods resulting in a win-win for sponsors and sites. We’ll continue to transform patient recruitment by delivering an improved process designed to increase enrollment and site/primary investigator productivity.”

The mission of the MedTech Breakthrough Awards is to honor excellence and recognize the innovation, hard work and success in a range of health and medical technology categories, including Telehealth, Clinical Administration, Patient Engagement, Electronic Health Records (EHR), Virtual Care, Medical Devices, Medical Data & Privacy, and many more. This year’s program attracted thousands of nominations from over 18 different countries throughout the world.

“The ability to find, recruit, and enroll participants is a huge challenge for clinical trials, resulting in 80% of them being delayed, and the majority of participant referrals are not even fully qualified,” said Steve Johansson, Managing Director at MedTech Breakthrough. “By delivering fully consented and medically qualified participants directly to sites, sponsors, and CROs, Science 37 eliminates common issues of disengaged site staff and having referrals diverted to competing studies. Science 37’s Patient Recruitment is more than a solution—it’s a leap forward in clinical trial efficiency and innovation—and we’re thrilled to recognize the entire Science 37 team for taking home our ‘Clinical Efficiency Innovation Award’ in 2024.”

About MedTech Breakthrough

Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the MedTech Breakthrough Awards program is devoted to honoring excellence and innovation in medical & health technology companies, products, services and people. The MedTech Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough healthcare and medical companies and products in categories that include Patient Experience & Engagement, Health & Fitness, Medical Devices, Clinical Administration, Connected Healthcare, Medical Data, Healthcare Cybersecurity and more. For more information visit MedTechBreakthrough.com. 

Tech Breakthrough LLC does not endorse any vendor, product or service depicted in our recognition programs, and does not advise technology users to select only those vendors with award designations. Tech Breakthrough LLC recognition consists of the opinions of the Tech Breakthrough LLC organization and should not be construed as statements of fact. Tech Breakthrough LLC disclaims all warranties, expressed or implied, with respect to this recognition program, including any warranties of merchantability or fitness for a particular purpose.

About Science 37

Science 37’s mission is to accelerate clinical research by enabling universal trial access for patients. Through our solutions; the Metasite™ and Patient Recruitment, we accelerate enrollment by expanding the reach of clinical trials to patients beyond the traditional site and rigorously qualifying patients prior to referring them to a traditional site. Our solutions are powered by a proprietary technology stack with in-house medical and operational experts that enhance quality through standardized workflows and best-in-class study orchestration. To learn more, visit www.science37.com, or email science37@science37.com.

To view studies that Science 37 is actively recruiting for, please visit https://studies.science37.com/current-studies/.

Media Inquiries

Science 37
PR@science37.com 

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.